Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review-Reference-Cited by-同舟云学术

Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review

Published:2023-07-31 Issue:5 Volume:23 Page:547-558
ISSN:1175-3277
Container-title:American Journal of Cardiovascular Drugs
language:en
Short-container-title:Am J Cardiovasc Drugs

Author:

Khan Muhammad Shayan,Ghumman Ghulam Mujtaba^ORCID,Baqi Abdul,Shah Jay,Aziz Muhammad,Mir Tanveer,Tahir Ayesha,Katragadda Srinivas,Singh Hemindermeet,Taleb Mohammed,Ali Syed Sohail

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40256-023-00593-6.pdf

Reference52 articles.

1. Kopin L, Lowenstein C. Dyslipidemia. Ann Intern Med. 2017;167(11):ITC81–96. https://doi.org/10.7326/AITC201712050.

2. Miller M. Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM. 2009;102(9):657–67. https://doi.org/10.1093/qjmed/hcp065.

3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168–209. https://doi.org/10.1016/j.jacc.2018.11.002.

4. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256(20):2823–8.

5. Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999–2006. JAMA. 2009;302(19):2104–10. https://doi.org/10.1001/jama.2009.1672.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status and future perspectives of FGF21 analogues in clinical trials;Trends in Endocrinology & Metabolism;2024-05

2. Assessing the Benefits of Lifestyle Influences on Cardiovascu-lar Health After Acute Coronary Syndrome;Balneo and PRM Research Journal;2024-03-31

3. Role of fenofibrate in multiple sclerosis;European Journal of Medical Research;2024-02-09

4. How to Handle Elevated Triglycerides: Life after PROMINENT;Current Atherosclerosis Reports;2023-12

5. Effectiveness and Safety of Fenofibrate in Routine Treatment of Patients with Hypertriglyceridemia and Metabolic Syndrome;Diseases;2023-10-13